NO20053657L - Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater - Google Patents

Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater

Info

Publication number
NO20053657L
NO20053657L NO20053657A NO20053657A NO20053657L NO 20053657 L NO20053657 L NO 20053657L NO 20053657 A NO20053657 A NO 20053657A NO 20053657 A NO20053657 A NO 20053657A NO 20053657 L NO20053657 L NO 20053657L
Authority
NO
Norway
Prior art keywords
bisphosphonates
delivery
transmucosal
vaginal delivery
improved formulations
Prior art date
Application number
NO20053657A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053657D0 (no
Inventor
Giovanni M Pauletti
Chris E Clendening
Original Assignee
Umd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umd Inc filed Critical Umd Inc
Publication of NO20053657D0 publication Critical patent/NO20053657D0/no
Publication of NO20053657L publication Critical patent/NO20053657L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A61F6/12—Inserters or removers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20053657A 2003-01-22 2005-07-27 Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater NO20053657L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/349,029 US6905701B2 (en) 1997-06-11 2003-01-22 Formulations for transmucosal vaginal delivery of bisphosphonates
PCT/US2004/000902 WO2004067063A2 (en) 2003-01-22 2004-01-14 Improved formulations for transmucosal vaginal delivery of bisphosphonates

Publications (2)

Publication Number Publication Date
NO20053657D0 NO20053657D0 (no) 2005-07-27
NO20053657L true NO20053657L (no) 2005-10-19

Family

ID=32823695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053657A NO20053657L (no) 2003-01-22 2005-07-27 Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater

Country Status (12)

Country Link
US (1) US6905701B2 (ja)
EP (1) EP1587470A2 (ja)
JP (1) JP2006515889A (ja)
CN (1) CN1741779A (ja)
AU (1) AU2004207456A1 (ja)
BR (1) BRPI0406635A (ja)
CA (1) CA2514109A1 (ja)
IL (1) IL169694A0 (ja)
MX (1) MXPA05007791A (ja)
NO (1) NO20053657L (ja)
NZ (1) NZ541776A (ja)
WO (1) WO2004067063A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163826A1 (en) * 1997-06-11 2005-07-28 Umd, Inc. Medicated tampon
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
PT1506041E (pt) 2002-05-10 2007-12-28 Hoffmann La Roche Ácido ibandrónico para o tratamento e a prevenção da osteoporose
AU2003286796A1 (en) * 2002-10-31 2004-06-07 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
SI1790347T1 (sl) 2002-12-20 2015-03-31 F. Hoffmann-La Roche Ag Formulacija z visokim odmerkom ibandronata
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US20060100566A1 (en) * 2004-11-05 2006-05-11 Women's Medical Research Group, Llc Apparatus and method for the treatment of dysmenorrhea
ES2366654T3 (es) * 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Biofosfonatos para tratar la endometriosis.
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
WO2008039864A1 (en) * 2006-09-26 2008-04-03 Novavax, Inc. Emulsion formulations for transdermal delivery of poorly water soluble active agents
ATE464916T1 (de) * 2006-11-06 2010-05-15 Lohmann & Rauscher Gmbh & Co Kg Produkt zur versorgung von entzündungen, druckstellen und/oder aphten im oralbereich sowie verwendung eines solchen produkts
EP2088996A1 (en) * 2006-11-17 2009-08-19 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
US20080254098A1 (en) * 2007-04-11 2008-10-16 Ehrlich Shelley R Neural tube birth defect reduction with folic acid delivery in catamenial hygiene products
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
EP2266578A4 (de) * 2008-03-18 2011-08-17 Dikovskiy Aleksander Vladimirovich Pharmazeutische zusammensetzung zur prävention und behandlung von knochenresorption unterschiedlicher ätiologie
JP5902318B2 (ja) * 2011-12-29 2016-04-13 ラボラトリオス アンドロマコ ソシエダッド アノニマ メロキシカム、および有効成分の放出を調節する薬剤を含み、女性における連続使用避妊に用いられることができる膣リング
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
FI3773501T3 (fi) * 2018-03-29 2023-12-19 The Materia Company Ltd Emättimensisäinen valmiste
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
WO2004067063A3 (en) 2004-11-04
JP2006515889A (ja) 2006-06-08
US20040005345A1 (en) 2004-01-08
IL169694A0 (en) 2007-07-04
NZ541776A (en) 2008-01-31
WO2004067063A2 (en) 2004-08-12
NO20053657D0 (no) 2005-07-27
CA2514109A1 (en) 2004-08-12
MXPA05007791A (es) 2005-09-30
EP1587470A2 (en) 2005-10-26
CN1741779A (zh) 2006-03-01
AU2004207456A1 (en) 2004-08-12
BRPI0406635A (pt) 2005-12-06
US6905701B2 (en) 2005-06-14

Similar Documents

Publication Publication Date Title
NO20053657L (no) Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater
BR0113134A (pt) Aplicação vaginal de bisfosfonatos
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
DK1339411T3 (da) Anvendelse af zoledronsyre til smertebehandling
DE60141145D1 (ja)
ATE497745T1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
CY1105370T1 (el) Μεθοδος θepαπειας των κλιμακτηριακων διαταραχων στις εμμηνοπαυσιακες και μετεμμηνοπαυσιακες γυναικες
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
WO2006058140A3 (en) Capsaicinoid gel formulation and uses thereof
NO20052306L (no) Dispergerbare farmasoytiske blandinger.
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DK1202725T3 (da) Metode til behandling af symptomer på hormonal variation, herunder hedeture
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
TW200503782A (en) New formulations and use thereof
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
DE602004018119D1 (de) Vorrichtung zur wirkstofffreisetzung mit einer netzhülse
TW200509998A (en) Controlled release of highly soluble agents
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
BR0314362A (pt) Método para previnir ou reduzir fraturas secundárias após fratura de quadril
CA2529983A1 (en) Preoperative treatment of post operative pain
MXPA05008347A (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.
ECSP045056A (es) Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion
TW200600089A (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain
ECSP003564A (es) ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application